49Z Stock Overview Operates as a bioconvergence company in North America, Europe, Asia, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
BICO Group AB (publ) Competitors Price History & Performance
Summary of share price highs, lows and changes for BICO Group Historical stock prices Current Share Price SEK 2.80 52 Week High SEK 5.47 52 Week Low SEK 2.53 Beta 2.38 1 Month Change -1.89% 3 Month Change -28.68% 1 Year Change -46.93% 3 Year Change -89.43% 5 Year Change n/a Change since IPO -71.10%
Recent News & Updates
Lab14 GmbH acquired Nanoscribe GmbH from BICO Group AB (publ) (OM:BICO) for €26 million. Nov 29
Lab14 GmbH acquired Nanoscribe GmbH from BICO Group AB (publ) (OM:BICO) for €26 million. Nov 28
Third quarter 2024 earnings released: kr3.49 loss per share (vs kr1.00 loss in 3Q 2023) Nov 26
Forecast to breakeven in 2026 Nov 15 BICO Group AB (publ) to Report Fiscal Year 2024 Final Results on Mar 20, 2025
BICO Group AB (publ), Annual General Meeting, May 08, 2025 Oct 09 See more updates
Lab14 GmbH acquired Nanoscribe GmbH from BICO Group AB (publ) (OM:BICO) for €26 million. Nov 29
Lab14 GmbH acquired Nanoscribe GmbH from BICO Group AB (publ) (OM:BICO) for €26 million. Nov 28
Third quarter 2024 earnings released: kr3.49 loss per share (vs kr1.00 loss in 3Q 2023) Nov 26
Forecast to breakeven in 2026 Nov 15 BICO Group AB (publ) to Report Fiscal Year 2024 Final Results on Mar 20, 2025
BICO Group AB (publ), Annual General Meeting, May 08, 2025 Oct 09
Second quarter 2024 earnings released: kr1.10 loss per share (vs kr12.73 loss in 2Q 2023) Aug 21
BICO Group AB Announces Management Changes Jul 10
New minor risk - Profitability Jun 11
No longer forecast to breakeven Jun 11
BICO Group AB (publ) Elects Alexandra Gatzemeyer as Member of the Board of Directors May 23
First quarter 2024 earnings released: kr0.40 loss per share (vs kr1.67 loss in 1Q 2023) May 07
BICO Group AB (publ) Announces the Appointment of Anders Fogelberg as Chief Commercial Officer, Effective June 13, 2024 Apr 19
BICO Group AB (publ) Announces Gerry Mackay and Erik Gatenholm Decline Re-Election of the Board of Directors Apr 16
BICO Group AB (publ) to Report Fiscal Year 2024 Results on Feb 19, 2025 Mar 15 BICO Group AB (publ) to Report Q3, 2024 Results on Nov 13, 2024
Full year 2023 earnings released: kr24.05 loss per share (vs kr12.94 loss in FY 2022) Feb 22
New major risk - Revenue and earnings growth Feb 20
BICO Group AB (publ) Appoints Catharina Nordlund as Global Head of HR Jan 25
Group Chief Financial Officer recently bought €75k worth of stock Nov 18 BICO Group AB (publ) to Report Fiscal Year 2023 Results on Mar 15, 2024
Second quarter 2023 earnings released: kr12.73 loss per share (vs kr0.68 profit in 2Q 2022) Aug 23 BICO Group AB (publ) Announces Chief Executive Officer Changes
Beos Light Industrial Germany 1 Fund, a fund managed by BEOS AG agreed to acquire property on Wagner-Régeny-Straße 15 from BICO Group AB (publ) (OM:BICO) for €21 million. Aug 04
BICO Group AB (publ) Elects Gerry Mackay to Its Board of Directors May 10
First quarter 2023 earnings released: kr1.67 loss per share (vs kr0.68 loss in 1Q 2022) May 08
BICO Group AB (publ) to Report Fiscal Year 2023 Results on Feb 20, 2024 May 05
Full year 2022 earnings released: kr13.00 loss per share (vs kr3.97 loss in FY 2021) Feb 22
Independent Chairman of the Board recently sold €747k worth of stock Jan 14
BICO Group AB Appoints Marius Balger as Chief Operating Officer, Effective March 1, 2023 Jan 06
BICO Group AB Announces the Appointment of Jacob Thordenberg as Group CFO Jan 03
BICO Group AB (publ) to Report Q1, 2023 Results on May 04, 2023 Nov 22
Now 28% undervalued Nov 16
Third quarter 2022 earnings released Nov 10
BICO Group AB (publ) to Report Q2, 2023 Results on Jul 20, 2023 Nov 10 BICO Group Announces Appointment of Nomination Committee 2023
Forecast breakeven date moved forward to 2022 Oct 22
Second quarter 2022 earnings released Aug 24
Forecast breakeven date moved forward to 2022 Jul 21
Now 22% undervalued after recent price drop Jun 14
First quarter 2022 earnings released: kr0.68 loss per share (vs kr0.90 loss in 1Q 2021) May 19 BICO Group AB (publ) to Report Fiscal Year 2023 Results on Feb 22, 2023
BICO Group Adds Åsa Hillsten as SVP and Head of IR May 12
BICO Group AB (publ) (OM : BICO) acquired Allegro 3D for $11 million. May 08
BICO (publ) Appoints Mikael Engblom as Interim CFO May 02
Now 23% undervalued after recent price drop Apr 28
High number of new and inexperienced directors Apr 27 BICO Group AB (Publ) Announces Board Appointments
Co-Founder recently bought €94k worth of stock Mar 04
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 24
BICO Reaches Beneficial and Sustainable Solution with Organovo Feb 24
DISPENDIX, A BICO Company, Announces That the I.DOT HT Non-contact Dispenser and the L.DROP Liquid Handler will be introduced at SLAS 2022 Feb 03
BICO Group AB Announces Statement Regarding Counterclaims in Patent Lawsuit by Organovo Against Cellink Jan 12
Co-Founder recently bought €1.9m worth of stock Dec 18
BICO Group AB (publ) (OM:BICO) agreed to acquire Biosero Llc. Dec 17
Third quarter 2021 earnings released Nov 12
Insider recently sold €1.1m worth of stock Sep 01
BICO Group AB (publ) (OM:BICO) acquired all outstanding shares in Advanced BioMatrix, Inc. for $18 million. Aug 28
CEO & Director recently sold €17m worth of stock Aug 25
Second quarter 2021 earnings released: kr0.89 loss per share (vs kr0.58 loss in 2Q 2020) Aug 21
CELLINK Receives Patent for Robotic Systems for Personalized and Automated Aesthetic Medical Procedures Jul 03
Cellink AB (publ) (OM:CLNK B) completed the acquisition of Discover Echo Inc. Jul 01
Cellink AB (publ) (OM:CLNK B) completed the acquisition of Nanoscribe GmbH for approximately €37 million. Jun 01 Cellink AB (publ) (OM:CLNK B) entered into an agreement to acquire Nanoscribe GmbH for €34 million.
First quarter 2021 earnings released May 13
Cellink AB (publ) (OM:CLNK B) entered into an agreement to acquire MatTek Corporation for $68 million. Mar 12
Cellink AB (publ) (OM:CLNK B) completed the acquisition of Ginolis Ltd from Verso Fund II of Verso Capital Oy, Finnvera plc and Innovestor Ventures for €65.7 million. Mar 03 Cellink AB (publ) to Report Fiscal Year 2021 Results on Mar 16, 2022
Cellink AB (publ) (OM:CLNK B) entered into an agreement to acquire Ginolis Ltd for €70 million. Feb 16
New 90-day high: €30.00 Feb 13
Cellink AB (publ) Announces Distribution Agreement Including New Products for Single-Cell RNA Sequencing and NGS Library Preparation Feb 09
Cellink Announces Third Year Extension of Collaboration with A Global Biopharmaceutical Company for Drug Discovery Jan 29
Cellink and Phasefocus Announces a Partnership to Bring Livecyte High Content Live Cell Imager to a Wider Audience Jan 20
New 90-day high: €25.25 Jan 04
Cellink AB (publ) Elects Aristotelis Nastos as Member of the Board of Directors Dec 19
New 90-day high: €21.65 Dec 17
CELLINK and Atelerix Team Up to Enable the Shipping At Room Temperature of Fragile 3D Bioprinted Constructs by the World's Bioprinting Community Dec 05
CELLINK to Help Develop 3D Bioprinted Personalised Scaffolds for Tissue Regeneration of Ankle Joint S as Part of the Triankle Project Nov 10
Full year earnings released - €1.47 loss per share Oct 22
Cellink AB (publ) to Report Second Half, 2020 Results on Oct 22, 2020 Oct 20 Shareholder Returns 49Z DE Life Sciences DE Market 7D 1.7% 0.1% 0.3% 1Y -46.9% -5.3% 6.9%
See full shareholder returns
Return vs Market: 49Z underperformed the German Market which returned 7.2% over the past year.
Price Volatility Is 49Z's price volatile compared to industry and market? 49Z volatility 49Z Average Weekly Movement n/a Life Sciences Industry Average Movement 7.0% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.8% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 49Z's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 49Z's volatility change over the past year.
About the Company BICO Group AB (publ) operates as a bioconvergence company in North America, Europe, Asia, and internationally. It operates through three segments: Bioprinting, Biosciences, and Bioautomation. The Bioprinting segment offers products, solutions, and services that enable proliferation of 3D cell culture and 3D printing.
Show more BICO Group AB (publ) Fundamentals Summary How do BICO Group's earnings and revenue compare to its market cap? 49Z fundamental statistics Market cap €203.00m Earnings (TTM ) -€148.33m Revenue (TTM ) €202.94m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 49Z income statement (TTM ) Revenue SEK 2.33b Cost of Revenue SEK 639.40m Gross Profit SEK 1.69b Other Expenses SEK 3.40b Earnings -SEK 1.70b
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 19, 2025
Earnings per share (EPS) -24.14 Gross Margin 72.57% Net Profit Margin -73.09% Debt/Equity Ratio 52.8%
How did 49Z perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/30 12:58 End of Day Share Price 2024/12/30 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources BICO Group AB (publ) is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Dylan van Haaften Bryan Garnier & Co Hanseung Yoo Bryan Garnier & Co Maria Vara Fernández Bryan Garnier & Co
Show 1 more analysts 
